Short Interest in SanBio Company Limited (OTCMKTS:SNBIF) Declines By 29.8%

SanBio Company Limited (OTCMKTS:SNBIF) saw a significant decline in short interest during the month of August. As of August 31st, there was short interest totalling 545,300 shares, a decline of 29.8% from the August 15th total of 776,900 shares. Based on an average daily volume of 2,400 shares, the short-interest ratio is currently 227.2 days.

SanBio Stock Performance

SNBIF stock remained flat at C$3.85 during mid-day trading on Monday. SanBio has a fifty-two week low of C$3.80 and a fifty-two week high of C$4.25. The firm’s fifty day moving average is C$3.85 and its 200-day moving average is C$3.84.

About SanBio

SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson's disease, spinal cord injury, and Alzheimer's disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis.